Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

These trials, including those from companies like Eisai and UCB, have demonstrated robust target ... JMP Securities also reiterated a Buy rating on the stock with a $83.00 price target. TipRanks ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play the stock amid the recent price decline ...

The underwritten offering of common stock at $31 per share comes shortly ... with the IPO expected to price sometime next week. Brand new biotech Eyconis, a spinout set up to advance the ...

Baird raised the firm’s price target on Biogen (BIIB) to $300 from $294 and keeps an Outperform rating on the shares. The firm said Biogen partner Eisai’s request for the EMA’s CHMP to reexamine the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks. The results ...